FDA warns Mylan on PR plant violations

The FDA has warned Mylan ($MYL) of "significant violations" of manufacturing rules at a plant in Caguas, Puerto Rico, where inspectors found the drugmaker failed to properly test for product uniformity and didn't fully investigate a batch failure. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.